Achieve new heights in PTM analysis with confidence and speed.
Define critical quality attributes (CQAs) and streamline processes from early to late-stage development with in-depth peptide mapping solutions for next-generation protein therapeutics and standard monoclonal antibodies (mAbs).
Explore the latest trending topics
Technical note
Accurate localization of PTMs with a single injection workflow
Gain the additional power of electron activated dissociation (EAD) capabilities for isomer differentiation while maintaining the advantages of the traditional collision-induced dissociation (CID) technique.
Technical note
Enhance PQA identification during ADC development with confident proteoform ID, and payload localization.
Gain a level of characterization beyond traditional LC separation and CID based workflows to provide critical information to guide analytical strategies throughout ADC development.
Technical note
Gain in-depth and comprehensive characterization of a new-generation Cys-conjugated ADC
A full characterization workflow of a complex ADC. EAD enabled peptide mapping provides confident identification of T-DXd peptides with partial or complete payload conjugation for accurate DAR determination and impurity assessment.
Develop peptide mapping strategies for the unknown and the routine.
The requirements of peptide mapping analyses change during the drug development process. In early development, full characterization and determining the appropriate product quality attributes (PQAs) are key and depend on extremely complex data processing and analysis. In late development, throughput is a priority to quickly process samples and analyze PQAs. Over the course of biotherapeutic production, continuous monitoring of PTMs and chemical variations is critical to maintain overall product safety and efficacy.
Address the need for complete sequence coverage, comprehensive determination of PTMs and reliable high-throughput monitoring assays with LC-MS solutions designed to address the challenges of peptide mapping at all stages of the therapeutic development pipeline.
Workflow
Reach new depths of peptide mapping analysis.
Leverage the power of EAD to identify and fully characterize potential critical quality attributes (CQAs) and challenging PTMs, such as glycosylation and disulfide linkages, with speed and reproducibility.
Enable in-depth analysis of next-generation protein therapeutics and mAbs with an EAD-based LC-MS platform method for peptide mapping. Visually intuitive pre-built software workflows allow for simple data interpretation and PTM monitoring.
Resources
Technical note
Enable differentiation of isomeric amino acids
Superior characterization and monitoring of product quality attributes using an EAD-based multi-attribute method (MAM) to achieve more detail on isomeric amino acids than CID alone.
Technical note
Achieve accurate localization of PTMs with a single injection platform method
Leverage the additional power of EAD capabilities for isomer differentiation while maintaining the advantages of traditional CID techniques.
Technical note
Achieve superior sequence and disulfide linkage confirmation
Maintain labile PTMs for site-specific characterization and perform comprehnsive mapping of etanercept using and EAD-based workflow.
Technical note
Be agile with flexible workflows to address data analysis needs throughout development
Distinct workflow structures support diverse analytical biotherapeutic applications from discovery and development to production and quality attribute monitoring.
Workflow
Gain confidence in the routine. Simplify peptide mapping and PTM monitoring to maximize productivity.
Take advantage of pre-built LC-MS workflows and visually intuitive compliance-ready data analysis solutions to speed up routine peptide mapping and anslysis.
Resources
Technical note
Routine characterization of biosimilars
Maintain quality for biotherapeutics throughout development and production with a fast, reproducible and robust method for biologic subunit analysis.
Technical note
Routine peptide mapping with a small footprint
Discover simple solutions for complex characterization challenges.
Technical note
Accurate localization of PTMs
Gain the additional power of EAD capabilities for isomer differentiation while maintaining advantages of traditional CID technique.
Webinar
Comprehensive characterization of protein therapeutics
Dive deeper in to characterization workflows and discuss the advantages of alternative fragmentation techniques EAD to develop a comprehensive understanding of protein therapeutics.
Technical note
Visualize PTMs throughout development with intuitive data analysis workflows
Distinct workflow structures support diverse analytical biotherapeutic applications, from discovery and development through to production and quality attribute monitoring.
Technical note
Enable differentiation of isomeric amino acids
Superior characterization and monitoring of product quality attributes using an EAD-based multi-attribute method (MAM) to achieve more detail on isomeric amino acids than CID alone.
Technical note
Achieve accurate localization of PTMs with a single injection platform method
Leverage the additional power of EAD capabilities for isomer differentiation while maintaining the advantages of traditional CID techniques.
Technical note
Achieve superior sequence and disulfide linkage confirmation
Maintain labile PTMs for site-specific characterization and perform comprehnsive mapping of etanercept using and EAD-based workflow.
Technical note
Be agile with flexible workflows to address data analysis needs throughout development.
Distinct workflow structures support diverse analytical biotherapeutic applications from discovery and development to production and quality attribute monitoring.
Technical note
Routine characterization of biosimilars
Maintain quality for biotherapeutics throughout development and production with a fast, reproducible and robust method for biologic subunit analysis.
Brochure
Routine peptide mapping with a small footprint
Discover simple solutions for complex characterization challenges.
Technical note
Charge heterogeneity monitoring to comprehensive biotherapeutic characterization
Take full advantage of advanced characterization capabilities of the EAD enabled ZenoTOF 7600 system with simple conversion from icIEF-UV/MS to EAD based LC/MS.
Technical note
Enhanced sensitivity to identify low abundant proteoforms
A 4x increase in sensitivity enables detection and confident identification of challenging proteoforms like deamidation
Technical note
Gain in-depth and comprehensive characterization of a new-generation Cys-conjugated ADC
A full characterization workflow of a complex ADC. EAD enabled peptide mapping provides confident identification of T-DXd peptides with partial or complete payload conjugation for accurate DAR determination and impurity assessment.
Pursue simpler, faster and more accurate product quality profiles. Reclaim time for innovation and reduce overall analytical testing burden with software solutions for product quality attribute (PQA) monitoring.
Take control of the unknowns. Gain confident sequence confirmation and localization of post-translational modifications (PTMs) at the sub-unit level.
Confidently select lead candidates and ensure reproducible product quality. Discover fast and reliable solutions that simplify identification and characterization of complex molecules at the intact level.
